Novo Nordisk A/S (NYSE:NVO) Trading Up 4% – Should You Buy?

Novo Nordisk A/S (NYSE:NVO) shares shot up 4% on Tuesday . The company traded as high as $36.75 and last traded at $36.7070. 18,830,779 shares traded hands during trading, a decline of 22% from the average session volume of 24,192,109 shares. The stock had previously closed at $35.29.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulator (NICE) recommended Wegovy to reduce heart‑attack and stroke risk, potentially expanding NHS access to ~1.2 million people — a material demand/access win for Novo. British drug-cost watchdog recommends use of Novo’s Wegovy to lower heart risks
• Positive Sentiment: Novo launched a Wegovy subscription/pricing program and partnerships with telehealth providers to lower effective monthly cost for self‑pay patients — a defensive commercial move to protect share and adherence. NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
• Positive Sentiment: Company released a cross‑trial indirect comparison (ORION study) saying oral Wegovy showed greater mean weight loss and lower discontinuation vs Lilly’s oral candidate — a messaging/data point Novo can use to blunt competitive headlines. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Pipeline progress: Novo is advancing next‑gen programs (triple agonist UBT251 in early global studies) — supports longer‑term growth optionality beyond current GLP‑1 dynamics. Novo Nordisk Triple Agonist Progress Spurs Questions On Valuation Gap
• Neutral Sentiment: Market reaction shows resilience: early trading held firm/edged up as investors appear to have partly priced in competitive risk and are focusing on access and pricing initiatives. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly (LLY) won FDA approval for its oral GLP‑1 (Foundayo/orforglipron) with a commercial launch imminent and forecasts for multi‑billion dollar sales — intensifies competition and could erode Novo’s oral market leadership and pricing power. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Multiple outlets report Lilly’s approval and launch (Foundayo) will put fresh pressure on Novo’s Wegovy franchise and has already boosted Lilly shares — a near‑term headwind for NVO revenue growth expectations. Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
• Negative Sentiment: Policy risk: report that the U.S. administration is preparing up to 100% tariffs on branded drugs for companies not striking price deals could hit U.S. pricing/sales if applied broadly — an added macro/regulatory downside for major pharma exporters including Novo. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Some analyst commentary and downgrades have appeared amid the intensified competitive backdrop, which can amplify negative sentiment around near‑term valuation and guidance risk. Novo Nordisk: I Admit That I Was Really Wrong (Downgrade)

Analyst Ratings Changes

A number of equities research analysts recently issued reports on NVO shares. HSBC reissued a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective on the stock. Finally, Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Four investment analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Up 1.1%

The business’s 50 day moving average is $44.44 and its 200-day moving average is $50.07. The company has a market cap of $164.61 billion, a PE ratio of 10.61, a P/E/G ratio of 8.69 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 52.74%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. raised its position in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares in the last quarter. Capital International Investors increased its stake in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the last quarter. Boston Partners acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $310,199,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares during the period. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 851.6% in the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after buying an additional 4,302,126 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.